TaperCommunitytranylcypromine
Boxed Warning
Suicidality risk in children, adolescents, and young adults under 25 during initial antidepressant treatment.
Tranylcypromine is a non-selective irreversible MAOI structurally related to amphetamine, giving it a faster onset and mild stimulating quality compared with phenelzine. Same dietary and drug-interaction restrictions.
10mg tablets
Tablets: 10mg
Category C
Irreversible inhibition of MAO-A and MAO-B; mild releasing effect on monoamines via amphetamine-like structure.
Slow taper. Some members report mild stimulant-like withdrawal (fatigue, low motivation) given the amphetamine-related structure.
Same washout requirements as other irreversible MAOIs. Mild dependence-like features are reported but uncommon.
1-3 days after stopping
1-2 weeks
3-6 weeks
Mood and energy can take 1-2 months to stabilize
Toxicity
Same as phenelzine: tyramine-induced hypertensive crisis, serotonin syndrome, sympathomimetic interactions.
Parnate (tranylcypromine) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Neutral, high-authority entity references.
Official prescribing information and safety notices.
Primary literature cited in this taper guide.
Evidence-based deprescribing and prescribing standards.
Clinician-facing references on tapering protocols.
Long-running communities documenting withdrawal experience.
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.
Pharmacokinetics
Hepatic.
Browse our map of deprescribing-informed providers worldwide.